Journal
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
Volume 44, Issue 2, Pages 157-167Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/08923973.2021.2020284
Keywords
Indole derivatives; NF-kappa B; inflammation; LPS; macrophage
Categories
Funding
- National Natural Science Foundation of China [U1801283, 31870908, 81860615]
- Yunnan University [2018FY001-001]
- Guangdong Provincial Science and Technology Program [2019B030301009]
- SZU Top Ranking Project [86000000210]
- Project of Innovative Research Team of Yunnan Province [202005AE160005]
- Yunnan Science and Technology Office [2018FY001-001]
Ask authors/readers for more resources
This study demonstrated the anti-inflammatory effects of XCR-5a both in vitro and in vivo, showing its ability to suppress pro-inflammatory cytokines production and inhibit immune cell infiltration by suppressing NF-kappa B signaling activation. XCR-5a could be a potential drug candidate for treating inflammatory diseases.
Context: Few studies on anti-inflammatory drugs with indole groups have been published. This is the first study that demonstrates the anti-inflammatory effects of indole derivative XCR-5a in vitro and in vivo. Objective: This study aimed to discover more anti-inflammatory drugs with indole groups and investigate their anti-inflammatory mechanisms. Materials and methods: First, a series of indole derivatives was synthesized, then screened for XCR-5a, a compound with anti-inflammatory effects. Second, the in vitro production of IL-1 beta, IL-6, TNF-alpha, inducible nitric oxide synthase (iNOS), and cyclo-oxygenase-2 (COX-2) in lipopolysaccharide (LPS)-induced primary cells of mice pretreated with XCR-5a was determined using qPCR and ELISA. Finally, the effect of XCR-5a on LPS-induced NF-kappa B signaling activation was determined by Western blotting. An in vivo mouse sepsis model was established. In mouse lung tissue, the production of IL-1 beta, IL-6, and TNF-alpha was determined and H&E staining was performed. Results: Our findings showed that XCR-5a could suppress the production of LPS-induced IL-1 beta, IL-6, and TNF-alpha, as well as mRNA expression of iNOS and COX-2. Pretreatment with XCR-5a inhibited the LPS-induced inflammatory response in septic mice in vivo by decreasing pro-inflammatory cytokines production in serum and reducing immune cell infiltration. Mechanistically, XCR-5a suppressed LPS-induced activation of the NF-kappa B signaling pathway. Conclusions: XCR-5a has anti-inflammatory effects in vitro and in vivo. Therefore, XCR-5a could be a potential drug candidate for the treatment of inflammatory diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available